AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023
October 12, 2023 – Clinical Trials – AstraZeneca, COVID-19, IDWeek 2023, clinical trials
Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection
FluMist Quadrivalent data support the potential for a self-administered influenza vaccine to expand
access to an important tool for prevention
11 October 2023 — Cambridge, UK — AstraZeneca will showcase new preclinical, clinical and real-world data across its Vaccines & Immune Therapies portfolio at the 12th annual IDWeek conference 11-15 October, reinforcing the important role of long-acting antibodies and vaccines to protect at-risk individuals from the increased burdens of common infectious respiratory diseases. The company will present 15 abstracts at the event, featuring three oral presentations, including one late-breaking oral and 12 poster presentations.
Data will be presented featuring:
- Real-world evidence demonstrating the continued and disproportionate burden of COVID-19 on immunocompromised individuals
- Beyfortus (nirsevimab), a long-acting antibody for prevention of disease due to respiratory syncytial virus (RSV)
- Self-administration of the FluMist Quadrivalent intranasal influenza vaccine, a potential new option for expanding access to a seasonal influenza vaccine
- AZD3152, an investigational long-acting antibody against COVID-19
Iskra Reic, executive vice president of Vaccines & Immune Therapies, AstraZeneca, said: “Our ambition is to provide long-lasting immunity to millions of people where the burden of disease is greatest. This year at IDWeek, our data provide the strongest evidence to date that the burden of COVID-19 on those who are immunocompromised remains significant and disproportionate. In addition, we’ll share updated data on AZD3152 and Beyfortus and the important role these long-acting antibodies can play in preventing COVID-19 and RSV among the most vulnerable patients, ensuring that no one is left behind.”
Continued evidence on the importance of passive immunisation as an approach to protect immunocompromised individuals
AstraZeneca will present updated in vitro neutralisation data for the investigational long-acting antibody AZD3152 against historical and emerging COVID-19 variants. Additionally, updated data on Beyfortus, a long-acting antibody recently approved by the US Food and Drug Administration (FDA) for the prevention of RSV lower respiratory tract disease (LRTD) in infants, will be presented, reinforcing Beyfortus as an important and differentiated intervention to provide protection for the most at-risk babies. Passive immunisation provides infection-fighting antibodies directly to immunocompromised patients who are unlikely to elicit an adequate immune response to traditional vaccinations.
Real-world data highlight continued unmet need and disproportionate impact of COVID-19 for the immunocompromised
Three presentations, including two orals, from the ground-breaking INFORM real-world evidence study in England reveal the increased burden of severe COVID-19 outcomes facing all individuals with immunocompromised conditions compared to the general population, even when fully vaccinated against the virus, and highlight the need for additional protection to target this population. The data also examine the increased risk for people with specific immunocompromising conditions, such as solid and haematologic malignancies, solid organ transplant and end-stage renal disease.
Pioneering new ways to protect against influenza
AstraZeneca will present a summary of the evidence supporting the potential of self-administration of FluMist, its intranasal, injection-free, live attenuated influenza vaccine (LAIV). The study evaluates the potential for self- and caregiver-administered LAIV to enable more equitable access to the influenza vaccine for communities which lack easy access, thereby helping to meet vaccination targets.
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca.com.
